Clinical Trials Logo
  1. Home
  2. Corona Virus Infection
  3. NCT04579588
  4. Details
NCT04579588 Clinical Trial

Understanding Immunity to the Flu Vaccine in COVID-19 Patients

Corona Virus Infection Clinical Trial

Official title:
Understanding Immunity to the Flu Vaccine in COVID-19 Patients

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04579588
Other study ID # IRB-58356
Secondary ID 5U19AI057229-17
Status Recruiting
Phase
First received
Last updated
Start date October 29, 2020
Est. completion date March 2026

Study information
Verified date April 2024
Source Stanford University
Contact SNP Center Inquiry
Phone (650) 521-7237
Email snpcenterallergy_inquiry@stanford.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to measure immunity to the flu vaccine over time in patients who had COVID-19. Adults who have been diagnosed with COVID-19 as well as controls without COVID-19 will be invited to participate in this study.

Recruitment information / eligibility
Status Recruiting
Enrollment 200
Est. completion date March 2026
Est. primary completion date March 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 64 Years
Eligibility Inclusion Criteria: - Adults enrolled in study 55689 (NCT04373148) or the general population - Adults diagnosed with severe or moderate COVID-19 at least 2 months prior enrollment - Adults without COVID-19 diagnosis for controls Exclusion Criteria: - Received the influenza vaccine less than 4 months ago - Pregnant or lactating - Patients with special risks attendant to venipuncture - Use of immunomodulatory medications - Immunodeficiency or autoimmune disease

Study Design

Related Conditions & MeSH terms

Intervention

Biological:
• Flu shot
All participants will receive a single shot of the flu vaccine

Locations
Country Name City State
United States Stanford University Palo Alto California

Sponsors (2)
Lead Sponsor Collaborator
Stanford University National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Testing immunity to the flu vaccine over time 2 months
Primary Testing immunity to the flu vaccine over time 1 month
See also
  Status Clinical Trial Phase
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT04578210 - Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia Phase 1/Phase 2
Completed NCT05065827 - Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
Completed NCT04720794 - A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion N/A
Enrolling by invitation NCT04659486 - Adolescents With COVID-19/MIS-C at HCFMUSP N/A
Completed NCT04598620 - Non-invasive Prognostication of COVID-19 Patients by Use of Biomarkers in Exhaled Breath Condensate
Completed NCT05517941 - Effect of Active Cycle Breathing Technique Along With Incentive Spirometer on COVID19 Patient N/A
Recruiting NCT04565782 - Corona Virus Infection Among Liver Transplant Recipients
Recruiting NCT04480333 - Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831 Phase 1
Active, not recruiting NCT04558476 - Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation Phase 2
Completed NCT05639998 - BBV152/BBV154 Heterologus Prime-Boost Study Phase 2
Completed NCT04526769 - Detecting SARS-CoV-2 in Tears
Completed NCT04523246 - Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents Early Phase 1
Withdrawn NCT04386447 - Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19 Phase 2
Completed NCT05736926 - Anal Fissure Among Survivors of COVID-19 Virus Infection.
Recruiting NCT04583566 - Differential Expression of Cytokines, Transcriptome and miRNA in Coronavirus Disease 2019 (COVID-19) Egyptian's Patients
Completed NCT04643678 - Anakinra in the Management of COVID-19 Infection Phase 2/Phase 3
Terminated NCT03331445 - Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections Phase 2
Recruiting NCT04573348 - T Cells Response to SARS COV 2 Peptides
Completed NCT04615936 - Nasal Photodisinfection COVID-19 Proof of Concept Study N/A